Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...